<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-3U3XM157</identifier><date>2023</date><creator>Avsec, Damjan</creator><creator>Mlinarič-Raščan, Irena</creator><creator>Podgornik, Helena</creator><creator>Škerget, Matevž</creator><relation>documents/doc/3/URN_NBN_SI_doc-3U3XM157_001.pdf</relation><relation>documents/doc/3/URN_NBN_SI_doc-3U3XM157_001.txt</relation><format format_type="issue">1</format><format format_type="volume">74</format><format format_type="type">article</format><format format_type="extent">str. 67-74</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID_HOST">144693763</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-3U3XM157</identifier><language>slv</language><publisher publisher_location="Ljubljana">Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">duvelizib</subject><subject language_type_id="slv">idelalizib</subject><subject language_type_id="slv">Kronična limfocitna levkemija</subject><subject language_type_id="slv">PI3K</subject><subject language_type_id="slv">Zdravljenje</subject><title>Phosphatidylinositol 3-kinase in chronic lymphocytic leukemia</title><title>Tarčno zdravljenje kronične limfocitne levkemije z zaviralci fosfatidilinozitol 3-kinaze targeting</title></Record>